Gilteritinib, Venetoclax and Azacitidine Produce 60.5 Percent Composite Remission in Relapsed FLT3-Mutated AML

Marrow at Day 14 to 21 Set the Dose

Mei Chen of the department of hematology and Nainong Li of the hematopoietic stem cell transplantation center, both at Fujian Medical University Union Hospital in Fuzhou, are the corresponding authors on a retrospective review that deliberately narrows its own denominator. Patients given single-agent gilteritinib as maintenance after allogeneic transplant, without active leukemia, were pulled out of the analysis, leaving only those treated for disease that was measurably present. The nine authors sit across the Fujian Institute of Hematology, the Fujian Provincial Key Laboratory on Hematology, the university's Translational Medicine Center on Hematology and its transplant center, and every one of them declares no competing interests on a paper about a three-drug commercial regimen.

Early marrow clearance or aplasia at day 14 to 21 occurred in 63.2 percent, and that assessment is what triggered adjustment. Venetoclax duration was cut or the drug was held in 78.9 percent of patients. The authors present the regimen as feasible in selected heavily pretreated patients specifically when paired with that marrow-guided adaptation.

Which Co-Mutation Mattered

Having already failed a FLT3 inhibitor did not predict a worse outcome, and 63.2 percent of the cohort carried that prior exposure into treatment. Co-mutation in the RAS or mitogen-activated protein kinase pathway did predict worse, tracking with both lower composite remission and shorter survival. Paired profiling at the point of failure separated two patterns, one in which the FLT3 mutation persisted and one in which it was lost, and the authors argue that repeat testing, not the baseline genotype, should steer whatever comes next.

Only the structured abstract was available for this report. The transplant rate, the assay platform used for FLT3 molecular monitoring, and the sampling schedule behind it all sit in the subscription-only full text, and none of them can be quoted here.

A Second Venetoclax Paper the Same Day

The same journal posted a second real-world venetoclax analysis on July 29, and the two were briefly hard to tell apart from their metadata. They are separate studies. The other, from Duke Cancer Institute with Thomas LeBlanc as corresponding author, covers 160 patients on first-line venetoclax-based therapy who were ineligible for intensive chemotherapy, and asks how cycle 1 exposure relates to outcome after adjusting for CYP3A inhibitor use. Composite complete response was 55 percent overall and 66 percent among patients with an evaluable marrow biopsy, at a median of 41.5 days. Patients who received 21 days of venetoclax plus or minus 3 in cycle 1 had higher response rates and got there faster than those on the standard 28 days, and greater cycle 1 dose or exposure bought nothing. Hematologic adverse events requiring treatment modification were significantly associated with achieving response, at p below .001.

Why This Matters to the APO|APE Reader

The FLT3-loss pattern in the Fujian failure profiles is the finding with the most immediate consequence for testing practice, because a patient whose leukemia returns without the mutation that justified gilteritinib is no longer a candidate for the drug that produced the remission. Reading that requires a molecular sample drawn at relapse as well as at diagnosis, and the paper reports paired profiling as something the center did as routine practice. Set against the Duke series, where treatment modification for cytopenias tracked with response instead of against it, both papers point the same way on venetoclax scheduling in cohorts that no trial protocol would have kept on full dosing.